XML 61 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCK BASED COMPENSATION (Tables)
9 Months Ended
Sep. 30, 2013
STOCK BASED COMPENSATION  
Schedule of stock based compensation expense

Stock based compensation has been reported within expense line items on the consolidated statement of operations for the three and nine months ended September 30, 2012 and 2013 as shown in the following table (in $000s):

 

 

 

Three Months Ended
September 30,

 

Nine months Ended
September 30,

 

 

 

2012

 

2013

 

2012

 

2013

 

General and administrative

 

$

59

 

82

 

$

202

 

199

 

Research and development

 

16

 

15

 

49

 

44

 

Discontinued operations

 

1

 

 

36

 

 

Stock-based compensation costs before income taxes

 

$

76

 

$

97

 

$

287

 

$

243

 

 

Schedule of stock option activity

 

Cyclacel Pharmaceuticals, Inc.

 

Number of
options
outstanding

 

Weighted
average
exercise
price

 

Weighted
average
remaining
contractual
term (years)

 

Aggregate
intrinsic
value ($000)

 

Options outstanding at December 31, 2012

 

463,023

 

$

26.61

 

5.58

 

$

347

 

Granted

 

32,697

 

$

3.01

 

 

 

 

 

Exercised

 

 

$

 

 

 

 

 

Cancelled/forfeited

 

(8,001

)

$

18.55

 

 

 

 

 

Options outstanding at September 30, 2013

 

487,719

 

$

25.16

 

5.20

 

178

 

Unvested at September 30, 2013

 

76,885

 

$

6.07

 

8.56

 

57

 

Vested and exercisable at September 30, 2013

 

410,834

 

$

28.74

 

4.57

 

121

 

 

Schedule of restricted stock units activity

Summarized information for restricted stock unit activity for the nine months ended September 30, 2013 is as follows:

 

 

 

Restricted Stock
Units

 

Weighted Average
Grant
Date Value Per Share

 

Non-vested at December 31, 2012

 

39,377

 

$

5.34

 

Granted

 

85,097

 

$

5.71

 

Forfeited

 

(5,226

)

$

5.00

 

Non-vested at September 30, 2013

 

119,248

 

$

5.62